These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12715145)

  • 21. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acute coronary syndromes without ST-elevation -- treatment].
    Weber M; Hamm C
    Dtsch Med Wochenschr; 2003 Feb; 128(6):273-6. PubMed ID: 12571797
    [No Abstract]   [Full Text] [Related]  

  • 24. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
    Subbarao VD; Phillips J; Stouffer GA
    Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
    Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
    Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study.
    Valgimigli M; Campo G; Arcozzi C; Malagutti P; Carletti R; Ferrari F; Barbieri D; Parrinello G; Percoco G; Ferrari R
    J Am Coll Cardiol; 2007 Jul; 50(2):138-45. PubMed ID: 17616297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microvascular obstruction in acute coronary syndromes: onward to a new therapeutic target.
    Schwartz RS
    Catheter Cardiovasc Interv; 2005 Oct; 66(2):170-2. PubMed ID: 16142803
    [No Abstract]   [Full Text] [Related]  

  • 32. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.
    EPILOG Investigators
    N Engl J Med; 1997 Jun; 336(24):1689-96. PubMed ID: 9182212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization.
    Lenzen MJ; Boersma E; Bertrand ME; Maier W; Moris C; Piscione F; Sechtem U; Stahle E; Widimsky P; de Jaegere P; Scholte op Reimer WJ; Mercado N; Wijns W;
    Eur Heart J; 2005 Jun; 26(12):1169-79. PubMed ID: 15802360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheolytic therapy combined with intragraft abciximab for treatment in acute myocardial infarction.
    Vallakati A; Mastrine L; Ayzenberg S
    J Invasive Cardiol; 2013 Feb; 25(2):E33-5. PubMed ID: 23388236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J; Kastrati A; Schühlen H; Dibra A; Dotzer F; von Beckerath N; Bollwein H; Pache J; Dirschinger J; Berger PP; Schömig A;
    Circulation; 2004 Dec; 110(24):3627-35. PubMed ID: 15531766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic plaque passivation for the reduction of recurrent cardiac events in acute coronary syndromes.
    Monroe VS; Kerensky RA; Rivera E; Smith KM; Pepine CJ
    J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):23S-30S. PubMed ID: 12644337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Inhibitors of platelet glycoprotein IIb-IIIa in cardiology].
    Obradović S; Gligić B; Djordjević D; Jovicić A; Romanović R; Ratković N; Dincić D; Orozović V; Nikolić G
    Vojnosanit Pregl; 2001; 58(1):65-72. PubMed ID: 11419288
    [No Abstract]   [Full Text] [Related]  

  • 40. The glycoprotein IIb/IIIa receptor inhibitor (abciximab) in ST-segment elevation myocardial infarction.
    Mesquita A; Baptista J; Palos J; Seabra-Gomes R
    J Invasive Cardiol; 1999 Jun; 11(6):379-82. PubMed ID: 10745556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.